Stockreport

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

SeaStar Medical Holding Corporation  (ICU) 
PDF Data illustrate the potential of QUELIMMUNE™? with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children w [Read more]